GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has entered into definitive securities purchase agreements for a public offering expected to raise approximately $6 million in gross proceeds. The offering involves the sale of about 9.2 million units, each consisting of one share of common stock and warrants to purchase additional shares, priced at $0.65 per unit. Roth Capital Partners is serving as the exclusive placement agent for the offering.
The company plans to use the net proceeds for working capital and general corporate purposes, supporting its ongoing development of immunotherapies and vaccines targeting cancer and infectious diseases. The offering is set to close around July 2, 2025, pending customary closing conditions. This financial move underscores GeoVax's commitment to advancing its clinical programs, including a next-generation COVID-19 vaccine and a novel oncolytic solid tumor gene-directed therapy.
For more details on the offering, interested parties can access the final prospectus supplement and accompanying prospectus on the SEC's website once available. This announcement highlights GeoVax's strategic efforts to secure funding for its innovative healthcare solutions, potentially impacting the treatment landscape for cancer and infectious diseases.